Ohr Pharmaceutical has expanded its Scientific Advisory Board (SAB) with the addition of two prominent ophthalmologists who will join the current panel of retinal ophthalmology experts focused on advancing the company’s Squalamine eye drop program into clinical efficacy trials.
David S. Boyer, M.D. of Retina-Vitreous Associates Medical Group in Los Angeles and Lawrence J. Singerman, M.D. of Retina Associates of Cleveland were appointed to Ohr Pharmaceutical’s SAB to advise the company on its clinical programs, regulatory strategy, and to provide strategic guidance to support the development of Squalamine.
“We are pleased to be working with thought leaders in the retina community of the caliber of Drs. Boyer and Singerman,” Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical stated in the press release. “Their addition to our ophthalmic SAB, together with their past experience in the clinical advancement of numerous FDA approved retinal therapeutics, including Eylea® and Lucentis®, will immensely help the company move the Squalamine eye drop program forward into its first clinical trial, which is expected to be in in the third quarter of 2012.”
Dr. Boyer is a board-certified ophthalmologist and senior partner at Retina-Vitreous Associates Medical Group. Dr. Boyer, who is also a published writer and lecturer, is a clinical professor with the University of Southern California. He has been involved in trials studying age-related macular degeneration, diabetic retinopathy, and cytomegalovirus retinitis.
Dr. Singerman is also a board-certified ophthalmologist and published author, and is the founder of Retina Associates of Cleveland, where he and eight other retina specialists see patients throughout Northern Ohio. Dr. Singerman is active in the field of clinical research and has been a principal investigator in more than 75 multicenter clinical trials sponsored by NIH and pharmaceutical companies.
Preclinical testing has demonstrated the Squalamine eye drop formulation as safe to ocular tissues. The formulation achieves in excess of target anti-angiogenic concentrations in the tissues of the back of the eye. In May 2012, the Squalamine eye drop program was granted Fast Track Designation by the U.S. FDA.
For more information, visit www.ohrpharmaceutical.net
Let us hear your thoughts below: